<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224625</url>
  </required_header>
  <id_info>
    <org_study_id>R13-051</org_study_id>
    <nct_id>NCT02224625</nct_id>
  </id_info>
  <brief_title>Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth</brief_title>
  <official_title>Randomized and Observer-blinded Study to Evaluate the Cumulative Irritation and Contact Sensitizing Potential of One Finished Test Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medline Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medline Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the irritation properties of CHG cloth. Some Subjects will also have the product
      applied to see if they become sensitized to repeated applications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the Irritation Study (30 subjects), patches containing CHG, vehicle, saline, CHG
      comparator or sodium lauryl sulfate (a product that is expected to produce a slight skin
      irritation) will be placed on the same spot of your skin every day for 21 days. The skin will
      be examined every day.

      The Sensitization Study (200 total subjects) place patches containing CHG, vehicle, saline,
      CHG comparator on the skin 3 times a week for 3 weeks. Following a two-week rest period the
      patches will be reapplied for 48 hours and assessed out to 72 hours thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grading Scale for Visual Evaluation of Skin Condition</measure>
    <time_frame>21 Days for Irritation (N=39). 35 Days for Sensitization (N=249)</time_frame>
    <description>Irritation: 21 days of patching (total). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit.
Sensitization: 35 days (21 days of patching followed by 14 days rest and subsequent patch). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit. SLS was not tested.
Grade 0 = No irritation Grade 1 = Minimal erythema Grade 2 = Definite erythema Grade 3 = Erythema and papules Grade 4 = Edema Grade 5 = Erythema, edema and papules Grade 6 = Vesicular eruption Grade 7 = Strong reaction spreading</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>2% CHG Cloth</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorhexidine Gluconate 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cloth</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipients on cloth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DynaHex (2% CHG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorhexidine Gluconate 2% solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>0.9% sodium chloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Lauryl Sulfate (SLS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium lauryl sulfate to produce mild irritation as a positive control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% CHG Cloth solution</intervention_name>
    <description>Investigational CHG</description>
    <arm_group_label>2% CHG Cloth</arm_group_label>
    <other_name>Chlorhexidine Gluconate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vehicle Cloth</intervention_name>
    <description>Excipients from CHG cloth only</description>
    <arm_group_label>Vehicle Cloth</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>DynaHex (2% CHG)</arm_group_label>
    <other_name>DynaHex-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Negative control</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SLS</intervention_name>
    <description>Provides a slight irritation for a positive control</description>
    <arm_group_label>Sodium Lauryl Sulfate (SLS)</arm_group_label>
    <other_name>Sodium Lauryl Sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Free of skin disorders

          -  Signed consent

        Exclusion Criteria:

          -  Allergies to latex

          -  Topical or systemic steroids, antihistamines, antiinflammatory agents 7 days prior or
             during testing

          -  severe illness

          -  Pregnant (females)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Pullman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioScience Laboratories</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioScience Laboratories</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <results_first_submitted>February 5, 2016</results_first_submitted>
  <results_first_submitted_qc>April 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2016</results_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data to be shared with FDA</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>39 of the 249 participants participated in both the Irritation and Sensitization Studies.</recruitment_details>
      <pre_assignment_details>Participants received up to 5 products simultaneously on their skin. SLS was only used in the Irritation study (39 subjects) as a positive control.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2% CHG Cloth, Vehicle, DynaHex, Saline, SLS</title>
          <description>Chlorhexidine Gluconate 2% cloth solution Vehicle solution of 2% CHG cloth DynaHex (2% CHG) 0.9% Saline Sodium Lauryl Sulfate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Irritation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Sensitization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="249">Subjects from Irritation study also participated in Sensitization Study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants in the Sensitization study received the following 4 products ( 2% CHG cloth, Vehicle cloth, DynaHex and Saline). Participants in the Irritation study received the same 4 products in addition to SLS.</population>
      <group_list>
        <group group_id="B1">
          <title>2% CHG, Vehicle, DynaHex, Saline</title>
          <description>Chlorhexidine Gluconate 2% Cloth Solution Vehicle solution of CHG cloth DynaHex 2% CHG solution 0.9% Saline Sodium Lauryl Sulfate (only used in Irritation Study)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="249"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="16" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Grading Scale for Visual Evaluation of Skin Condition</title>
        <description>Irritation: 21 days of patching (total). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit.
Sensitization: 35 days (21 days of patching followed by 14 days rest and subsequent patch). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit. SLS was not tested.
Grade 0 = No irritation Grade 1 = Minimal erythema Grade 2 = Definite erythema Grade 3 = Erythema and papules Grade 4 = Edema Grade 5 = Erythema, edema and papules Grade 6 = Vesicular eruption Grade 7 = Strong reaction spreading</description>
        <time_frame>21 Days for Irritation (N=39). 35 Days for Sensitization (N=249)</time_frame>
        <population>Participants received more than one product at a time.</population>
        <group_list>
          <group group_id="O1">
            <title>2% CHG Cloth</title>
            <description>Chlorhexidine Gluconate 2%
2% CHG Cloth: CHG solution on cloth</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cloth</title>
            <description>Excipients on cloth
Vehicle Cloth: Excipients from CHG cloth only</description>
          </group>
          <group group_id="O3">
            <title>DynaHex (2% CHG)</title>
            <description>Chlorhexidine Gluconate 2% solution
Active Comparator: 2% CHG solution</description>
          </group>
          <group group_id="O4">
            <title>Saline</title>
            <description>0.9% sodium chloride
Saline: Negative control</description>
          </group>
          <group group_id="O5">
            <title>Sodium Lauryl Sulfate (SLS)</title>
            <description>Sodium lauryl sulfate to produce mild irritation as a positive control
SLS: Provides a slight irritation for a positive control</description>
          </group>
        </group_list>
        <measure>
          <title>Grading Scale for Visual Evaluation of Skin Condition</title>
          <description>Irritation: 21 days of patching (total). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit.
Sensitization: 35 days (21 days of patching followed by 14 days rest and subsequent patch). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit. SLS was not tested.
Grade 0 = No irritation Grade 1 = Minimal erythema Grade 2 = Definite erythema Grade 3 = Erythema and papules Grade 4 = Edema Grade 5 = Erythema, edema and papules Grade 6 = Vesicular eruption Grade 7 = Strong reaction spreading</description>
          <population>Participants received more than one product at a time.</population>
          <units>Scores Ranging (0-7)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="249"/>
                <count group_id="O3" value="249"/>
                <count group_id="O4" value="249"/>
                <count group_id="O5" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Irritation Mean Visualization Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritation Mean Visualization Score Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O3" value="3.3" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="O4" value="0.7" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O5" value="3.0" lower_limit="3" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitization Mean Visualization Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitization Mean Visualization Score Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0.03" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events reported over a 21 (irritation) and 35 (sensitization) day period.</time_frame>
      <desc>Participants received up to 5 different products simultaneously during the study. Adverse skin reactions with known relationships to the products applied were reported individually. Non-skin related adverse events were also captured during the study but could not be associated directly with a particular treatment and are not included.</desc>
      <group_list>
        <group group_id="E1">
          <title>2% CHG Cloth</title>
          <description>Chlorhexidine Gluconate 2%
2% CHG Cloth: CHG solution on cloth</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Cloth</title>
          <description>Excipients on cloth
Vehicle Cloth: Excipients from CHG cloth only</description>
        </group>
        <group group_id="E3">
          <title>DynaHex (2% CHG)</title>
          <description>Chlorhexidine Gluconate 2% solution
Active Comparator: 2% CHG solution</description>
        </group>
        <group group_id="E4">
          <title>Saline</title>
          <description>0.9% sodium chloride
Saline: Negative control</description>
        </group>
        <group group_id="E5">
          <title>Sodium Lauryl Sulfate (SLS)</title>
          <description>Sodium lauryl sulfate to produce mild irritation as a positive control
SLS: Provides a slight irritation for a positive control</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="249"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="249"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="249"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Confidential information based on contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>C Beausoleil</name_or_title>
      <organization>Bioscience Labs</organization>
      <phone>406-587-5735</phone>
      <email>cbeausoleil@bioscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

